Cord blood cells engineered to fight deadly mold in first human test
NCT ID NCT07454122
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This early-phase trial tests a new approach for patients with invasive mold infections that are not responding to standard antifungal medicines. Researchers take natural killer (NK) cells from donated umbilical cord blood and genetically modify them to better target the mold. The study will enroll 10 adults to see if the treatment is safe and tolerable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Clinic Barcelona
Barcelona, Barcelona, 08036, Spain
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
genetically modified natural killer (NK) cells from umbilical cord blood
What this could lead to
If it works, this could offer a new treatment option for people with severe mold infections that don't respond to standard antifungal drugs.
What could go wrong
This is a very early, small phase 1 trial with only 10 participants, so it's mainly checking safety. It may not work, and there could be serious side effects from the cell infusion.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.